Section Arrow
LAB.NASDAQ
- Standard BioTools
Quotes are at least 15-min delayed:2025/12/09 09:02 EST
Pre Market
Last
 1.5
+0.04 (+2.74%)
Bid
1.46
Ask
1.5
High 1.5 
Low 1.45 
Volume 1.01K 
Regular Hours (Closed)
Last
 --
-- (--)
Day High 
-- 
Prev. Close
1.46 
1-M High
-- 
Volume 
-- 
Bid
1.46
Ask
1.5
Day Low
-- 
Open
-- 
1-M Low
-- 
Market Cap 
561.47M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.33/-0.20
Enterprise Value
588.23M
Balance Sheet
Book Value Per Share
1.04
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
174.43M
Operating Revenue Per Share
0.27
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZBHZimmer Biomet Holdings-------- 
Pre Market 92.75 0 0.00%
XTNTXtant Medical Holdings-------- 
Pre Market 0.7078 0 0.00%
XAIRBeyond Air Inc-------- 
Pre Market 1.15 +0.01 +0.88%
WOKWORK Medical Technology Group LTD.-------- 
Pre Market 4.89 +0.04 +0.82%
VVOSVivos Therapeutics-------- 
Pre Market 2.12 -0.04 -1.85%
Industry overview quotes are at least 15 minutes delayed
Business Description
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.